Stock has cleared an 11-week, 21% deep Consolidation Base this week. Currently, the stock is trading around just 0% away from its ideal buy price of INR 216. The stock is offering investors an opportunity to get on board at the current price.
The stock ended the week on a bullish note. It closed 16.5% up on a 290% greater volume than the 10-week average. You want to see a strong close on heavy volume like this before initiating a position. That signals institutional buying. You would also want to see the same price volume momentum continue in the coming weeks.
The key trend lines, 10 and 40-week moving averages are at a comfortable position. The current trends of both the averages are upward and the 10-week moving average is trending above the 40-week moving average. The current price of the stock is trading around 13.56% away from the 10-week moving average.
In the last twelve months, Gufic Biosciences Ltd has rallied nearly 132.1% as compared to 48.2% for the Nifty500. It has a Relative Strength Rating of 64. We definitely would like to see an improvement in the rating. At this point, we are taking a step back and focusing on the RS Line.
The Relative Strength Line of the stock is offering a lot of encouragement to investors. It has been making good progress in the last four weeks. The overall long-term trend of the line is also trending upward. If Gufic Biosciences Ltd can maintain this outperformance, it could make sense as a CANSLIM trade.
Gufic Biosciences Ltd stock has strong institutional support. The Accumulation/Distribution Rating of 'A+' represents heavy institutional buying over the past 13 weeks. Although the shares held by institutions dropped in the last quarter, the number of institutions holding the stock increased at the same time. This shows increasing interest among the institutions.
On the earnings front, Gufic Biosciences Ltd has an excellent EPS Rank of 96, which indicates consistency in earnings. The earnings and sales for the stock have grown by 18% and 9%, respectively over the past three years. Its 3-years earnings stability is 25, on a 0 to 99 scale (lower the better). Over the past five years, the earnings and sales for the stock have grown by 31% and 14%, respectively. The 5-years earnings stability is 22. The return on equity for the last reported year is 33%.
The stock belongs to the industry group of Medical-Generic Drugs. You would still want to see some improvement in the industry group rank for group. The current industry group rank is 99. The current price of Gufic Biosciences Ltd is -7% off from its 52-week high price and 182% above its 52-week low price.
The stock appears on our idealists: Growth 50, Minervini Trend Template.